Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Lumason
Generic Name
Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
DrugBank Accession Number
DB14105
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Structure
Thumb
Weight
Average: 744.964
Monoisotopic: 744.49172986
Chemical Formula
C38H74NaO10P
Synonyms
  • 1,2-dipalmitoyl-sn-glycero-3-phosphorylglycerol sodium salt
  • L-DPPG-Na
  • R-DPPG-Na
External IDs
  • MG-6060LS

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
LumaSonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)Injection, powder, lyophilized, for suspensionIntravenous; IntravesicalBracco Diagnostics Inc2021-04-01Not applicableUS flag
LumaSonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)KitIntravenous; IntravesicalBracco Diagnostics Inc2015-01-15Not applicableUS flag
LumaSonSodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (.19 mg/1mg) + 1,2-Distearoyllecithin (.19 mg/1mg) + Sulfur hexafluoride (60.7 mg/1mg)KitIntravenous; IntravesicalBracco Suisse SA2015-01-15Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
841B886EJ7
CAS number
200880-41-7
InChI Key
LDWIWSHBGAIIMV-ODZMYOIVSA-M
InChI
InChI=1S/C38H75O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h35-36,39-40H,3-34H2,1-2H3,(H,43,44);/q;+1/p-1/t35?,36-;/m1./s1
IUPAC Name
sodium (2R)-1-[(2,3-dihydroxypropyl phosphono)oxy]-3-(hexadecanoyloxy)propan-2-yl hexadecanoate
SMILES
[Na+].[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC

References

General References
Not Available
ChemSpider
29763754
RxNav
1599274

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Enrolling by InvitationDiagnosticCrohn's Disease (CD)1
4RecruitingDiagnosticAbdominal Injuries / Accidental Fall / Motor Vehicle Injury / Physical Abuse1
4RecruitingDiagnosticHepatic Disease1
4RecruitingDiagnosticRenal Malignant Tumor1
4RecruitingDiagnosticTrauma Abdomen1
4TerminatedDiagnosticLiver Biopsy1
4WithdrawnDiagnosticBone Marrow Transplant Complications / Sinusoidal Obstruction Syndrome (SOS) / Stem Cell Transplant Complications / Veno Occlusive Disease, Hepatic1
4WithdrawnDiagnosticNeonatal Post-Hemorrhagic Hydrocephalus1
3CompletedDiagnosticCoronary Artery Disease (CAD)2
3TerminatedDiagnosticCardiovascular Disease (CVD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionIntravenous; Intravesical
KitIntravenous; Intravesical
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5686060No1997-11-112017-11-11US flag
US10232061No2019-03-192038-07-06US flag
US10335502No2019-07-022038-07-06US flag

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000119 mg/mLALOGPS
logP8.32ALOGPS
logP10.94ChemAxon
logS-6.8ALOGPS
pKa (Strongest Acidic)1.89ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area151.65 Å2ChemAxon
Rotatable Bond Count40ChemAxon
Refractivity194.19 m3·mol-1ChemAxon
Polarizability88.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 21, 2018 16:23 / Updated on June 12, 2020 16:53